COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: Role of NFATc3

Molecular and Cellular Endocrinology

Volumn 382, Issue 2, 2014, Pages 998-1006

  Li, Hong ^a   Gao, Si ^a   Ye, Jiantao ^a   Feng, Xiaojun ^a   Cai, Yi ^b   Liu, Zhiping ^a   Lu, Jing ^a   Li, Qin ^a   Huang, Xiaoyang ^a   Chen, Shaorui ^a   Liu, Peiqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac hypertrophy; COX 2; ET 1; NFATc3

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCINEURIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOSPORIN A; ENDOTHELIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR NFAT3; TRANSCRIPTION FACTOR NFATC3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; HEART CELL CULTURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANF; ANGII; ANGIOTENIN II; ATRIAL NATRIURETIC FACTOR; BNP; BRAIN NATRIURETIC PEPTIDE; CARDIAC HYPERTROPHY; COX-2; CSA; CYCLOOXYGENASE-2; CYCLOSPORIN A; ENDOTHELIN SUBTYPE A RECEPTOR; ENDOTHELIN SUBTYPE B RECEPTOR; ENDOTHELIN-1; ET-1; ETAR; ETBR; NEONATAL RAT CARDIOMYOCYTES; NF-ΚB; NFATC3; NFATC4; NRCMS; NUCLEAR FACTOR OF ACTIVATED T CELLS C3; NUCLEAR FACTOR OF ACTIVATED T CELLS C4; NUCLEAR FACTOR-KAPPA B; PGE(2); PGS; PROSTAGLANDIN E2; PROSTAGLANDINS;

ANIMALS; ANIMALS, NEWBORN; CALCINEURIN; CARDIOMEGALY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOSPORINE; DINOPROSTONE; ENDOTHELIN-1; GENE EXPRESSION REGULATION; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NFATC TRANSCRIPTION FACTORS; NITROBENZENES; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSCRIPTION, GENETIC;

EID: 84890588761     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.11.012     Document Type: Article

References (50)

1. Abraham F., Sacerdoti F., De Leon R., Gentile T., Canellada A. Angiotensin II activates the calcineurin/NFAT signaling pathway and induces cyclooxygenase-2 expression in rat endometrial stromal cells. PLoS ONE 2012, 7:e37750.
2. Aydemir A.B.C., Minematsu H., Gardner T.R., Kim K.O., Ahn J.M., Lee F.Y.I. Nuclear factor of activated T cells mediates fluid shear stress- and tensile strain-induced Cox2 in human and murine bone cells. Bone 2010, 46:167-175.
3. Barry S.P., Townsend P.A. What causes a broken heart-molecular insights into heart failure. Int. Rev. Cell Mol. Biol. 2010, 284:113-179.
4. Bushdid P.B., Osinska H., Waclaw R.R., Molkentin J.D., Yutzey K.E. NFATc3 and NFATc4 are required for cardiac development and mitochondrial function. Circ. Res. 2003, 92:1305-1313.
5. Cialdella P., Pedicino D., Gustapane M., Santangeli P., Narducci M.L., Pelargonio G., Basile E., Giglio A.F., Pazzano V., Vitulano N., Bellocci F. Inflammatory markers in heart failure: hype or hope?. J. Cardiovasc. Med. (Hagerstown) 2011.
6. Cipollone F., Cicolini G., Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol. Therapeut. 2008, 118:161-180.
7. Corral R.S., Guerrero N.A., Cuervo H., Girones N., Fresno M. Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes. PLoS Negl. Trop. Dis. 2013, 7:e2034.
8. de Frutos S., Diaz J.M.R., Nitta C.H., Sherpa M.L., Bosc L.V.G. Endothelin-1 contributes to increased NFATc3 activation by chronic hypoxia in pulmonary arteries. Am. J. Physiol.-Cell Physiol. 2011, 301:C441-C450.
9. Delgado R.M., Nawar M.A., Zewail A.M., Kar B., Vaughn W.K., Wu K.K., Aleksic N., Sivasubramanian N., McKay K., Mann D.L., Willerson J.T. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 2004, 109:1428-1433.
10. Ferdinandy P., Schulz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 2007, 59:418-458.
11. Fiedler B., Wollert K.C. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc. Res. 2004, 63:450-457.
12. Fu J.J., Gao H., Pi R.B., Liu P.Q. An optimized protocol for culture of cardiomyocyte from neonatal rat. Cytotechnology 2005, 49:109-116.
13. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., Molkentin J.D., Alessandrini A., Woodgett J., Hajjar R., Michael A., Force T. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 2000, 151:117-130.
14. Harding P., Murray D.B. The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure. Life Sci. 2011, 89:671-676.
15. Iismaa S.E., Graham R.M. Dissecting cardiac hypertrophy and signaling pathways: evidence for an interaction between multifunctional g proteins and prostanoids. Circ. Res. 2003, 92:1059-1061.
16. Iwanaga Y., Kihara Y., Hasegawa K., Inagaki K., Yoneda T., Kaburagi S., Araki M., Sasayama S. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 1998, 98:2065-2073.
17. Kotlyar E., Vita J.A., Winter M.R., Awtry E.H., Siwik D.A., Keaney J.F., Sawyer D.B., Cupples L.A., Colucci W.S., Sam F. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J. Card. Fail. 2006, 12:122-127.
18. Lai J., Jin H., Yang R., Winer J., Li W., Yen R., King K.L., Zeigler F., Ko A., Cheng J., Bunting S., Paoni N.F. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am. J. Physiol. 1996, 271:H2197-208.
19. Le K., Li R.F., Xu S.W., Wu X.Q., Huang H.Q., Bao Y.X., Cai Y., Lan T., Moss J., Li C.X., Zou J., Shen X.Y., Liu P.Q. PPAR alpha activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4. Arch. Biochem. Biophys. 2012, 518:71-78.
20. Li R.F., Zheng W.H., Pi R.B., Gao J., Zhang H.J., Le P.W.K., Liu P.Q. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3 beta phosphorylation and inhibits cardiac hypertrophy. FEBS Lett. 2007, 581:3311-3316.
21. Lin Z., Murtaza I., Wang K., Jiao J., Gao J., Li P.F. MiR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2009, 106:12103-12108.
22. Lunde I.G., Kvaloy H., Austbo B., Christensen G., Carlson C.R. Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes. J. Appl. Physiol. 2011, 111:1278-1289.
23. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 2005, 5:472-484.
24. Martinez Rosas M. Cardiac remodeling and inflammation. Arch. Cardiol. Mex. 2006, 76(Suppl. 4):S58-66.
25. Mendez M., LaPointe M.C. Trophic effects of the cyclooxygenase-2 product prostaglandin E-2 in cardiac myocytes. Hypertension 2002, 39:382-388.
26. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., Grant S.R., Olson E.N. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
27. Murphy E., Eisner D.A. How does endothelin-1 cause a sustained increase in intracellular sodium and calcium which lead to hypertrophy?. J. Mol. Cell. Cardiol. 2006, 41:782-784.
28. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayama-Tomobe Y., Yamaguchi I. Myocardial fibrosis and Diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol. 2004, 43:1481-1488.
29. Peng H., Chen P., Cai Y., Chen Y., Wu Q.H., Li Y., Zhou R., Fang X. Endothelin-1 increases expression of cyclooxygenase-2 and production of interlukin-8 in hunan pulmonary epithelial cells. Peptides 2008, 29:419-424.
30. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. USA 2001, 98:6668-6673.
31. Qian J.Y., Leung A., Harding P., LaPointe M.C. PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1740-6.
32. Rebsamen M.C., Perrier E., Gerber-Wicht C., Benitah J.P., Lang U. Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction. Endocrinology 2004, 145:3135-3142.
33. Sakai S., Miyauchi T., Sakurai T., Kasuya Y., Ihara M., Yamaguchi I., Goto K., Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996, 93:1214-1222.
34. Schror K., Zimmermann K.C., Tannhauser R. Augmented myocardial ischaemia by nicotine-mechanisms and their possible significance. Brit. J. Pharmacol. 1998, 125:79-86.
35. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
36. Song H.J., Min Y.S., Shin C.Y., Jeong J.H., Sohn U.D. Activation of p38 MAPK is involved in endothelin-1-stimulated COX-2 expression in cultured feline esophageal smooth muscle cells. Mol. Cells 2006, 22:44-50.
37. Streicher J.M., Kamei K., Ishikawa T.O., Herschman H., Wang Y.B. Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. J. Mol. Cell. Cardiol. 2010, 49:88-94.
38. Sugiyama T., Yoshimoto T., Sato R., Fukai N., Ozawa N., Shichiri M., Hirata Y. Endothelin-1 induces cyclooxygenase-2 expression and generation of reactive oxygen species in endothelial cells. J. Cardiovasc. Pharm. 2004, 44:S332-S335.
39. Sun H., Xu B., Inoue H., Chen Q.M. P38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes. Cell. Signal. 2008, 20:1952-1959.
40. Suzuki T., Kumazaki T., Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem. Biophys. Res. Commun. 1993, 191:823-830.
41. Urso K., Alfranca A., Martinez-Martinez S., Escolano A., Ortega I., Rodriguez A., Redondo J.M. NFATc3 regulates the transcription of genes involved in T-cell activation and angiogenesis. Blood 2011, 118:795-803.
42. Wang B.H., Bertuci M., Ma J.Y., Adrahtas A., Cheung R.Y., Krum H. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clin. Exp. Pharmacol. Physiol. 2010, 37:912-918.
43. Wang K., Long B., Zhou J., Li P.F. MiR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J. Biol. Chem. 2010, 285:11903-11912.
44. Wong S.C., Fukuchi M., Melnyk P., Rodger I., Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 1998, 98:100-103.
45. Wu R., Laplante M.A., de Champlain J. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension 2005, 45:1139-1144.
46. Xu S.W., Little P.J., Lan T., Huang Y., Le K., Wu X.Q., Shen X.Y., Huang H.Q., Cai Y., Tang F.T., Wang H., Liu P.Q. Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in Apolipoprotein-E knockout mice fed a high cholesterol diet. Arch. Biochem. Biophys. 2011, 515:72-79.
47. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
48. Yun C.H., Kim J.G., Park B.S., Lee H.M., Kim D.H., Kim E.O., Park J.J., Park J.W., Damante G., Kim Y.I., Lee B.J. TTF-1 action on the transcriptional regulation of cyclooxygenase-2 gene in the rat brain. PLoS One 2011, 6:e28959.
49. Zamorano B., Carmona M.T. Prostaglandin-E2 and cyclic adenosine 3'-5'monophosphate levels in the hypertrophied rat heart. Biol. Res. 1992, 25:85-89.
50. Zidar N., Odar K., Glavac D., Jerse M., Zupanc T., Stajer D. Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?. J. Cell Mol. Med. 2009, 13:3753-3763.